Comstock Metals Ltd
- Country
- 🇦🇺Australia
- Ownership
- -
- Employees
- 11.2K
- Market Cap
- $101B
- Introduction
Carlisle Cos., Inc. engages in the design, manufacture, and distribution of building envelope products and energy solutions. It operates through the Carlisle Construction Materials (CCM) and Carlisle Weatherproofing Technologies (CWT) segments. The CCM segment produces single-ply roofing products and warranted roof systems and accessories for the commercial building industry, including ethylene propylene diene monomer (“EPDM”), thermoplastic polyolefin (“TPO”) and polyvinyl chloride (“PVC”) membrane, polyiso insulation, and engineered metal roofing and wall panel systems for commercial and residential buildings. The CWT segment produces spray polyurethane foam technologies, architectural metal, heating, ventilation and air conditioning (HVAC) hardware and sealants, below-grade waterproofing, and air and vapor barrier systems focused on the weatherproofing and thermal performance of the building envelope. The company was founded by Charles S. Moomy in 1917 and is headquartered in Scottsdale, AZ.
First Self-Amplifying mRNA COVID-19 Vaccine KOSTAIVE Receives European Commission Approval
CSL and Arcturus Therapeutics achieve a breakthrough as KOSTAIVE becomes the first self-amplifying mRNA COVID-19 vaccine approved by the European Commission for adults 18 and older.
CSL's Breakthrough: New Monthly Injectable Andembry Approved for Hereditary Angioedema
Australian regulators have approved Andembry, a novel engineered antibody treatment developed by CSL in Melbourne, offering new hope for hereditary angioedema patients.
CSL's Andembry (Garadacimab) Approved in Europe and UK for Hereditary Angioedema
The European Commission and the MHRA have approved CSL's Andembry (garadacimab) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older.
Phase 3 IMAGINE Trial of Clazakizumab in Kidney Transplant Rejection Fails to Meet Primary Endpoint
The Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with chronic active antibody-mediated rejection (caAMR), did not meet its primary efficacy outcome.
Phase 3 Trial of Clazakizumab Fails to Meet Primary Endpoint in Chronic Active Antibody-Mediated Kidney Transplant Rejection
A Phase 3 trial (IMAGINE) evaluating clazakizumab for chronic active antibody-mediated rejection (caAMR) in kidney transplant recipients was terminated early due to futility.
Arcturus/CSL COVID-19 Vaccine Shows Enhanced, Durable Immune Response Compared to Comirnaty
Arcturus Therapeutics and CSL's self-amplifying mRNA vaccine, ARCT-154, demonstrates superior immune responses compared to BioNTech/Pfizer's Comirnaty vaccine after 12 months.
Japan Approves CSL and Arcturus' Self-Amplifying mRNA COVID-19 Vaccine, Kostaive
Japan's MHLW has approved Kostaive, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine developed by CSL and Arcturus Therapeutics, targeting the JN.1 Omicron subvariant.
Japan Approves CSL and Arcturus Therapeutics' Updated sa-mRNA COVID-19 Vaccine Targeting JN.1 Variant
Japan's MHLW has approved CSL and Arcturus Therapeutics' updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®, for adults 18 and older.
Beyond LDL: Novel Cholesterol Targets and Therapies Show Promise in Reducing Cardiovascular Risk
Researchers are exploring treatments for lipoprotein(a), a genetically influenced cholesterol type unaffected by statins, with therapies showing potential in early trials.
Arcturus Therapeutics Announces Positive Clinical Updates and Financial Results for Q1 2024
Arcturus Therapeutics is on track to deliver initial 4 million doses of Kostaive® in Q3, with European approval decision expected in the same quarter.